- Home
- HOWL vs BRNS Comparison
HOWL vs BRNS Comparison
Compare HOWL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- BRNS
- Stock Information
- Founded
- HOWL 2017
- BRNS 2016
- Country
- HOWL United States
- BRNS United Kingdom
- Employees
- HOWL N/A
- BRNS N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- BRNS Health Care
- Exchange
- HOWL Nasdaq
- BRNS Nasdaq
- Market Cap
- HOWL 47.1M
- BRNS 42.8M
- IPO Year
- HOWL 2021
- BRNS 2021
- Fundamental
- Price
- HOWL $1.36
- BRNS $1.79
- Analyst Decision
- HOWL Strong Buy
- BRNS Strong Buy
- Analyst Count
- HOWL 3
- BRNS 1
- Target Price
- HOWL $8.33
- BRNS $3.00
- AVG Volume (30 Days)
- HOWL 554.2K
- BRNS 3.8M
- Earning Date
- HOWL 08-07-2025
- BRNS 08-07-2025
- Dividend Yield
- HOWL N/A
- BRNS N/A
- EPS Growth
- HOWL N/A
- BRNS N/A
- EPS
- HOWL N/A
- BRNS N/A
- Revenue
- HOWL $1,143,000.00
- BRNS $14,969,000.00
- Revenue This Year
- HOWL N/A
- BRNS N/A
- Revenue Next Year
- HOWL N/A
- BRNS N/A
- P/E Ratio
- HOWL N/A
- BRNS N/A
- Revenue Growth
- HOWL N/A
- BRNS 4381.74
- 52 Week Low
- HOWL $0.60
- BRNS $0.64
- 52 Week High
- HOWL $4.18
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- HOWL 60.96
- BRNS 69.66
- Support Level
- HOWL $1.25
- BRNS $1.69
- Resistance Level
- HOWL $1.44
- BRNS $2.01
- Average True Range (ATR)
- HOWL 0.10
- BRNS 0.37
- MACD
- HOWL 0.02
- BRNS 0.07
- Stochastic Oscillator
- HOWL 68.89
- BRNS 43.50
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.